You got that right! The solvency issues in Europe are killing the market. With Abbott releasing the clinical trial design on clinicaltrials.gov sometime within the 3 or 4 days, we have a chance to get some more new interest in the stock. It would be from people who follow Abbott instead of NBIX.
NBIX has plenty of cash and a maturing pipeline, so we can wait it out and let the results speak for themselves. It just should be worth so much more than it is now.